Giannis Mountzios: Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant NSCLC
Giannis Mountzios/LinkedIn

Giannis Mountzios: Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant NSCLC

Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on LinkedIn:

“Just out in International Association for the Study of Lung Cancer JTO an important academic collaborative effort to provide Real-World Data on trastuzumab deruxtecan Enhertu in patients with HER2 mutant NSCLC:

  • Among 168 patients with HER2mut NSCLC treated with TDXd, 59% were female and 56% never smokers
    mPFS was 7.2 months and mOS=18.3 months, consistent with Destiny-Lung01 cohorts
  • For untreated patients (N=18), ORR=72,2% !
  • Clear evidence of intracranial efficacy with icORR=74,1% (N=27, most previously treated with Rx), including an impressive 25.9% CR rate
  • Grade >=3 treatment-related AEs in 32%, with incidence of ILD in 14%, including 4 fatal cases

Underlies the importance of RWD for the implementation of ADCs in clinical practice

Happy to have co-ordinated the study on behalf of Greece

Title: Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort

Authors: Oliver Illini, Anna-Carina Hund, Hans-Georg Kopp, Mor Moskovitz, Giannis Mountzios, Wolfgang M. Brueckl, Martin Früh, Marie-Elisabeth Leßmann, Petros Christopoulos, Albrecht Stenzinger, Michael Thomas, Roni Gillis, Nir Peled, Fabian Acker, Alfredo Addeo, Andriani Charpidou, Christian Grohé, Laetitia Mauti, Sacha I. Rothschild, Sabine Schmid, Christian Schumann, Damien Urban, Robert Wurm, Simon Ekman, Marcus Skribek, Franziska Glanemann, Marcel Wiesweg, Christoph Jakob Ackermann, Sofia Agelaki, Petra Hoffknecht, Marko Jakopović, Jens Kern, David König, Katharina Kostenzer, Cornelia Kropf-Sanchen, Eckart Laack, David Lang, Laurenz Nagl, Georg Pall, Martin Reck, Waleed Kian, Anna T. Allemann, Jürgen Alt, David Araújo, Alexandros Bokas, Fabikan Hannah, Krainer-Jacobs Julie, Christoph Weinlinger, Adrianus Johannes de Langen, Evangelos Georgios Fergadis, Elena Fountzilas, Patrizia Froesch, Nikolaj Frost, Frank Griesinger, Franziska Jordan, Charisios Karanikiotis, Barbara Kiesewetter, Ippokratis Korantzis, Andrea Lopes Machado, Panagiota Economopoulou, Arnold Pilz, Patrick Reimann, Achim Rittmeyer, Akram Saad, Konstantinos Samitas, Karsten Schulmann, Riyaz Shah, Jan Alexander Stratmann, Hossein Taghizadeh, Kai Tammoscheit, Amanda Tufman, Jan-Phillip Weber, Ewald Wöll, Arschang Valipour, Tobias R. Overbeck, Maximilian J. Hochmair

Read the Article

Giannis Mountzios: Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant NSCLC

Other articles featuring Giannis Mountzios on OncoDaily.